

(TORCH) TOX-IgG, RV-IgG, CMV-IgG, HSV- II -IgG, HSV- I -IgG 5-in-1 Combo Rapid Test Panel
(Immunochromatography)

This package insert must be read carefully prior to use. Package insert instructions must be followed accordingly. Reliability of assay results cannot be guaranteed if there are deviations from the instructions in this package insert.

Product Name

(TORCH) TOX-IgG, RV-IgG, CMV-IgG, HSV- II -IgG, HSV- I -IgG 5-in-1 Combo Rapid Test Panel
(Immunochromatography)

Intended Use

Used for the qualitative detection of TORCH (TOX-IgG, RV-IgG, CMV-IgG, HSV- II -IgG, HSV- I -IgG) antibody in human serum or plasma to determine if someone is infected by TORCH.

Main Components

TOX-IgG: Sample pad, colloidal gold labeled anti-human IgG, nitrocellulose membrane coated with recombinant TOX antigen and goat anti-mouse IgG antibody, absorbent pad, PVC board

RV-IgG: Sample pad, colloidal gold labeled anti-human IgG, nitrocellulose membrane coated with recombinant RV antigen and goat anti-mouse IgG antibody, absorbent pad, PVC board

CMV-IgG: Sample pad, colloidal gold labeled anti-human IgG, nitrocellulose membrane coated with recombinant CMV antigen and goat anti-mouse IgG antibody, absorbent pad, PVC board

HSV- I -IgG: Sample pad, colloidal gold labeled anti-human IgG, nitrocellulose membrane coated with recombinant HSV- I antigen and goat anti-mouse IgG antibody, absorbent pad, PVC board

HSV- II -IgG: Sample pad, colloidal gold labeled anti-human IgG, nitrocellulose membrane coated with recombinant HSV- II antigen and goat anti-mouse IgG antibody, absorbent pad, PVC board

Storage and Expiry

Store as packaged in the sealed pouch at 4-30°C, keep out of hot and direct sunlight, keep in dry place, valid for 24 months. DO NOT FREEZE. Some protective measures should be taken in hot summer and cold winter to avoid high temperature or freeze-thaw. The product is humidity-sensitive and should be used immediately after being opened.

Care should be taken to protect the components of the kit from contamination. Do not use if there is evidence of microbial contamination or precipitation. Biological contamination of dispensing equipment, containers or reagents can lead to false results.

Sample Requirement

Sample Collection:

1. Serum: Use disposable syringe (vacuum blood collection tube) to extract a certain amount of

venous blood, and place at room temperature for blood coagulation, take the supernatant after centrifugation of blood for detection. Separate the serum from the clot or plasma from the packed cells as soon as possible to avoid any hemolysis.

2. Plasma: Use vacuum blood collection tube with anticoagulants to extract a certain amount of venous blood, and rock repeatedly, take plasma separation for detection.

3. EDTA, sodium citrate, sodium oxalate, heparin can be used as the anticoagulants.

Sample Storage:

Serum and plasma samples may be stored at 2-8°C for 3 days prior to assay, and at -20 °C for 2 years. If testing is delayed more than 7 days, the sample should be frozen (-20°C or colder). Repeat freeze and thaw for no more than 3 times.

Material Required But Not Provided

1. Sample Collection Container
2. Timer or Clock

Test Procedure

Instructions must be read entirely before taking the test. Allow the test device controls to equilibrate to room temperature for 30 minutes (20°C-30°C) prior to testing. Do not open the inner packaging until ready, it must be used in one hour if opened (Humidity: 20%~90%, Temp: 10°C-50°C)

1. Take off the outer packing, put the cassette onto the desk with the sample window up.
2. Apply 3 full drops of serum / plasma (80µl-100µl) vertically into the sample hole of cassette. *Avoid air bubble in the pipette, a bubble may prevent the complete transfer of sample and invalidate the test. Use a new pipette for each test performed, even if using the same sample.*
3. Observe the test results immediately within 15~30 minutes, the result is invalid over 35 minutes.

Result Judgment

POSITIVE: Two (2) distinct colored lines appear. One line should be in the control region (C) and the other line should be in the test region (T).

NEGATIVE: One (1) colored line appears in the control region(C). No apparent colored line appears in the test region (T).The negative result does not indicate the absence of analytes in the sample, it only indicates the level of tested analytes in the sample is less than cut-off level.


INVALID: No colored lines appear or control line fails to appear, indicating that the operator error or reagent failure. Verify the test procedure and repeat the test with a new testing device.

Note:

1. Any shade of color in the test region should be considered positive. Note that this is a qualitative test only, and cannot determine the concentration of analytes in the sample.
2. Insufficient sample volume, incorrect operating procedure or expired tests are the most likely

reasons for control line failure.

3. Control line color intensity of different items on the same cassette may be different, it is a normal phenomenon. The strength of the quality control line doesn't indicate the quality problem of the reagent, a test result that is clearly visible demonstrates the reagent is effective.



Limitation

- 1. This reagent is designed for the qualitative screening test. Concentration of analytes cannot be determined by this qualitative test.
- 2. The results of the reagent are only for clinical reference, which is not the only basis for clinical diagnosis and treatment. A confirmed diagnosis and treatment should only be made by a physician after all clinical and laboratory findings have been evaluated.
- 3. Negative result may occur when detecting short-term infected samples, indicate that the specific antibodies of TORCH does not exist or the concentration is below detection limit. If TORCH infection is still suspected, the sample should be collected 2 weeks later and carry the parallel detection with the first sample.
- 4. Negative results may occur at the beginning of acute infection, other testing method and analysis with clinical symptoms are suggested.
- 5. Results of patients who used to receive immunosuppressive therapy or with immune function

damage (for example HIV), may have a low serology reference value.

6. Positive results of the patients who used to receive blood transfusions or other blood products therapy, should be analyzed cautiously.

Performance Characteristics

TOX IgG:

- 1. Negative specificity: The results should all be negative when detecting kits of TOX IgG negative quality control samples.
- 2. Positive specificity: The results should all be positive when detecting kits of TOX IgG positive quality control samples.
- 3. Limit of detection: Positive results may occur when detecting TOX IgG quality control material.
- 4. Repeatability: The results should be consistent and the coloration degree should be consistent when detecting the TOX IgG standards by 10 kits of the same concentration.
- 5. Diagnostic specificity and sensitivity

A clinical evaluation was conducted on 431 samples (including 161 positive samples and 270 negative samples). The results are as follows:

Positive samples	161	TOX IgG test kits of MR	TOX IgG test kits of control group
		158/161 (98.1%)	158/161 (98.1%)
Negative samples	270	TOX IgG test kits of MR	TOX IgG test kits of control group
		267/270 (98.9%)	268/270 (99.3%)

6. Analytical sensitivity:

6.1 Cross-reactivity: The addition of HBV, HAV, EB- IgA, varicella virus, RF, ASO, ENA, ANA, MP, HAMA, high concentration IgG, systemic lupus erythematosus and other TORCH causative agents showed no cross-reactivity.

6.2 200 μmol/L bilirubin, 5.65mmol/L triglyceride, 10g/L hemoglobin has no effect on the detection result.

6.3 Hook effect: the hook effect will not occur even the TOX-IgG concentration as high of 504.21 IU/mL.

RV-IgG:

- 1. Negative specificity: The results should all be negative when detecting kits of RV-IgG negative quality control samples.
- 2. Positive specificity: The results should all be positive when detecting kits of RV-IgG positive quality control samples.
- 3. Limit of detection: The results should be positive when detecting RV-IgG quality control material.
- 4. Repeatability: The results should be consistent and the coloration degree should be consistent when detecting the RV-IgG standards by 10 kits of the same concentration.
- 5. Diagnostic specificity and sensitivity

A clinical evaluation was conducted on 402 samples (including 156 positive samples and 246 negative

samples). The results are as follows:

Positive samples	156	RV-IgG test kits of MR	RV-IgG test kits of control group
		153/156 (98.1%)	155/156 (99.4%)
Negative samples	246	RV-IgG test kits of MR	RV-IgG test kits of control group
		243/246 (98.8%)	243/246 (98.8%)

6. Analytical sensitivity:

6.1 Cross-reactivity: The addition of HBV, HAV, EB- IgA, varicella virus, RF, ASO,ENA, ANA, MP, HAMA, high concentration IgG, systemic lupus erythematosus and other TORCH causative agents showed no cross-reactivity.

6.2 200 µmol/L bilirubin, 10mmol/L total cholesterol, 6mmol/L triglyceride, 10g/L hemoglobin has no effect on the detection result.

6.3 Hook effect: the hook effect will not occur even the RV-IgG concentration as high of 577.25 IU/mL.

CMV IgG:

1. Negative specificity: The results should all be negative when detecting kits of CMV-IgG negative quality control samples.

2. Positive specificity: The results should all be positive when detecting kits of CMV-IgG positive quality control samples.

3. Limit of detection: Positive results may occur when detecting CMV-IgG quality control material.

4. Repeatability: The results should be consistent and the coloration degree should be consistent when detecting the CMV-IgG standards by 10 kits of the same concentration.

5. Diagnostic specificity and sensitivity

A clinical evaluation was conducted on 462 samples (including 185 positive samples and 277 negative samples). The results are as follows:

Positive samples	185	CMV-IgG test kits of MR	CMV-IgG test kits of control group
		183/185 (98.9%)	182/185 (98.4%)
Negative samples	277	CMV-IgG test kits of MR	CMV-IgG test kits of control group
		274/277 (98.9%)	273/277 (98.6%)

6. Analytical sensitivity:

6.1 Cross-reactivity: The addition of HBV, HAV, EB- IgA, varicella virus,RF, ASO,ENA, ANA, MP, HAMA, high concentration IgG, systemic lupus erythematosus and other TORCH causative agents showed no cross-reactivity.

6.2 200 µmol/L bilirubin, 10mmol/L total cholesterol, 6 mmol/L triglyceride, 10g/L hemoglobin has no effect on the detection result.

6.3 Hook effect: the hook effect will not occur even the CMV-IgG concentration as high of 702.12 U/mL .

HSV- I IgG:

1. Negative specificity: The results should all be negative when detecting kits of HSV- I IgG negative

quality control samples.

2. Positive specificity: The results should all be positive when detecting kits of HSV- I IgG positive quality control samples.

3. Limit of detection: Positive results may occur when detecting HSV- I IgG quality control material.

4. Repeatability: The results should be consistent and the coloration degree should be consistent when detecting the HSV- I IgG standards by 10 kits of the same concentration.

5. Diagnostic specificity and sensitivity

A clinical evaluation was conducted on 420 samples (including 148 positive samples and 272 negative samples). The results are as follows:

Positive samples	148	HSV- I IgG test kits of MR	HSV- I IgG test kits of control group
		146/148 (98.6%)	145/148 (98.0%)
Negative samples	272	HSV- I IgG test kits of MR	HSV- I IgG test kits of control group
		270/272 (99.6%)	268/272 (98.5%)

6. Analytical sensitivity:

6.1 Cross-reactivity: The addition of HBV, HAV, EB- IgA, varicella virus, RF, ASO, ENA, ANA, MP, and other TORCH causative agents showed no cross-reactivity.

6.2 1000 µmol/L bilirubin, 5.65mmol/L triglyceride, 10g/L hemoglobin has no effect on the detection result.

6.3 Hook effect: the hook effect will not occur even the HSV- I IgG concentration is high.

HSV- II –IgG:

1. Negative specificity: The results should all be negative when detecting kits of HSV- II IgG negative quality control samples.

2. Positive specificity: The results should all be positive when detecting kits of HSV- II IgG positive quality control samples.

3. Limit of detection: Positive results may occur when detecting HSV- II IgG quality control material.

4. Repeatability: The results should be consistent and the coloration degree should be consistent when detecting the HSV- II IgG standards by 10 kits of the same concentration.

5. Diagnostic specificity and sensitivity

A clinical evaluation was conducted on 415 samples (including 148 positive samples and 267 negative samples). The results are as follows:

Positive samples	148	HSV- II IgG test kits of MR	HSV- II IgG test kits of control group
		145/148 (98.0%)	146/148 (98.6%)

Negative samples	267	HSV- II IgG test kits of MR	HSV- II IgG test kits of control group
		262/267 (98.1%)	260/267 (97.4%)

6. Analytical sensitivity:

6.1 Cross-reactivity: The addition of HBV, HAV, EB-IgA, varicella virus, RF, ASO, ENA, ANA, MP, and other TORCH causative agents showed no cross-reactivity.

6.2 1000 µmol/L bilirubin, 5.65mmol/L triglyceride, 10g/L hemoglobin has no effect on the detection result.

6.3 Hook effect: the hook effect will not occur even the HSV- II IgG concentration is high.

Precaution

1. For IN VITRO diagnose only.
2. Do not use after the expiration date. Avoid using the test if the package is damaged.
3. This test provides a qualitative and visual outcome. A good light source is required for reading the results.
4. Avoid touching the nitrocellulose membrane with your fingers.
5. The test kit is disposable, not reusable.
6. The test result is invalid over 35 minutes.
7. The strength of the quality control line doesn't indicate the quality problem of the reagent, a test result that is clearly visible demonstrates the reagent is effective.
8. The color depth of the detection line was not necessarily associated with the antibody titer of the sample, positive results cannot be used as the only basis for diagnosis, further confirm experiment should be taken.
9. All samples and reagents should be considered potentially hazardous and handled in the same manner as an infectious agent after use. Laboratory chemical and biohazardous wastes must be handled and discarded in accordance with all local, regional, and national regulations.
10. Do not smoke, drink, or eat in areas where samples or kit reagents are being handled.
11. Do not use other kinds of quality control sample to test the reagent. Components of different batches cannot be exchanged for use to avoid erroneous results.
12. If the filtration speed is very slow or evens no filtration occurs, please test again with new sample. Samples with liquid migration velocity (stopwatch) less than 4.00mm/minis not suitable for this test kit, other detection methods are suggested to use.
13. The addition of HBV, autoantibody and EB virus IgA showed no cross-reactivity.
14. 1000 mol/L bilirubin, 5.65mmol/L triglyceride, 6.5g/L hemoglobin has no effect on the detection result.

KINGSMOOR SERVICE LIMITED

Address: 145 – 157 St John Street, London, EC1V 4PY, United Kingdom



	CE Mark		Keep Dry
	Do Not Reuse		Temperature Limitation
	Consult Instruction for Use		In Vitro Diagnostic Medical Product
	Batch Code		Caution
	European Union Representative		Contains Sufficient for <n> Tests
	Manufacturer		Date of Manufacture
	This side up		Fragile